PharmEasy has skipped the growth pill for profitability. This may lead to side effects

Healthtech company PharmEasy seems to finally be able to hold its head above water. The unicorn, which has been struggling with slowing growth, debt burden, and steep valuation cuts by investors, had something to cheer about when it turned Ebitda (earnings before interest, taxes, depreciation and amortisation) profitable in April this year. For venture capital and private equity money backed startups the fund crunch that started in 2022 has

Leave a Reply

Your email address will not be published. Required fields are marked *